Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engager
read at Endpoints ↗DealPositive
Roche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development.
The agreement could be worth up to $813 million in total, reflecting Roche’s interest in expanding its immuno-oncology pipeline.
The targeted T cell engager is positioned to compete with Amgen’s Imdelltra, indicating a potential new option for cancer immunotherapy.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Roche taps Zymeworks in up to $813M deal for preclinical T cell engager”
read at Endpoints ↗91 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that